Notably this included small cell lung cancer (SCLC) with Study B-005 (lurbinectedin) (16), EGFR mutated non-small cell lung cancer (NSCLC) with ARCHER 1050 (dacomitinib) (17) and triple negative breast cancer (TNBC) with IMMU-132-01 (sacituzumab govitecan) (18). This evidence concerns the gene EGFR and small cell lung carcinoma.